ReNeuron to automate stem cell stroke therapy production for Phase III trial

ReNeuron will automate processing of its stem cell-based stroke therapy ahead of planned Phase III trials using a system acquired from Sartorius Stedim Biotech (SSB) subsidiary, TAP Biosystems. The system – the Cellmate – will be used to make ReNeuron …

[Read the full article here]

Comments are closed.